Implementation of the Patented Medicine Prices Review Board’s proposed Guidelines will harm Canadian patients
Innovative Medicines Canada (IMC) is calling on Health Canada to direct the Patented Medicine Prices Review Board (PMPRB) to suspend its current Guidelines consultation process. If the PMPRB’s revised draft Guidelines are implemented without substantial […]